We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
+$46.9M
Cap. Flow %
3.47%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 10.46%
3 Consumer Staples 0.55%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
26
DELISTED
Acceleron Pharma
XLRN
$13.5M 1%
276,036
– –
CTMX icon
27
CytomX Therapeutics
CTMX
$586M
$13.4M 0.99%
+642,047
New +$10.2M
RGNX icon
28
Regenxbio
RGNX
$525M
$12.9M 0.96%
779,213
– –
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$12.7M 0.94%
37,143
– –
PFNX
30
DELISTED
Pfenex Inc.
PFNX
$11.9M 0.88%
960,877
-10,166
-1% -$150K
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$11.8M 0.87%
133,145
+10,101
+8% +$798K
DBVT
32
DBV Technologies
DBVT
$739M
$11.1M 0.82%
30,672
– –
BPMC
33
DELISTED
Blueprint Medicines
BPMC
$10.7M 0.79%
404,404
– –
SNDA icon
34
Sonida Senior Living
SNDA
$1.91B
$10.1M 0.75%
32,247
-4,660
-13% -$1.55M
SIOX
35
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$9.65M 0.71%
66,875
+15,625
+30% +$2.03M
ASRT
36
DELISTED
Assertio
ASRT
$9.06M 0.67%
+8,333
New +$9.37M
ACAD icon
37
Acadia Pharmaceuticals
ACAD
$4.61B
$8.74M 0.65%
245,240
-50,000
-17% -$1.76M
BLCM
38
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$8.54M 0.63%
42,119
-10,000
-19% -$1.79M
ALDX icon
39
Aldeyra Therapeutics
ALDX
$82.6M
$8.41M 0.62%
1,240,458
+283,265
+30% +$1.9M
AMGN icon
40
Amgen
AMGN
$203B
$8.12M 0.6%
50,000
+48,720
+3,806% +$7.66M
VBIV
41
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.96M 0.59%
108,679
– –
CASC
42
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.58M 0.56%
569,020
-22,130
-4% -$381K
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$7.37M 0.55%
+502,903
New +$6.15M
NEPT
44
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$7.17M 0.53%
4,786
– –
ARCT icon
45
Arcturus Therapeutics
ARCT
$450M
$6.46M 0.48%
+146,896
New +$6.61M
AFMD
46
DELISTED
Affimed
AFMD
$6.19M 0.46%
86,882
+20
+0% +$1.36K
ASMB icon
47
Assembly Biosciences
ASMB
$532M
$5.97M 0.44%
66,250
– –
ABEO icon
48
Abeona Therapeutics
ABEO
$313M
$5.92M 0.44%
70,515
– –
ARDX icon
49
Ardelyx
ARDX
$878M
$5.72M 0.42%
315,955
– –
OTIC
50
DELISTED
Otonomy, Inc.
OTIC
$5.72M 0.42%
205,986
+20,618
+11% +$513K
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $46.9M of net new capital in Q4 2015, opening 40 new positions and adding to 30 existing holdings. Its largest new stake was Allergan plc: 145,000 shares worth $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $22.7M trimmed.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.